Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Aptinyx Reports Results From Phase 2 Study Of NYX-458 In Cognitive Impairment Associated With Parkinson’s Disease And Dementia With Lewy Bodies And Provides Pipeline And Corporate Update; Will Undertake Cost-Cutting Measures And Explore Alternatives

NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company

APTX